Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Neurologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study.Headache. 2016; 56: 821-834
- Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019.J Headache Pain. 2020; 21: 137
- GBD 2016: still no improvement in the burden of Migraine.Lancet Neurol. 2018; 17: 929-930
- Global prevalence of chronic migraine: a systematic review.Cephalalgia. 2009; 30: 599-609
- Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American migraine prevalence and Prevention Study.Headache. 2012; 52: 1456-1470
- Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.Headache. 2008; 48: 1157-1168
- Migraine.Neurol Clin. 2019; 37: 631-649
- Rates, Predictors, and consequences of remission from chronic migraine to episodic migraine.Neurology. 2011; 76: 711-718
- Headache classification committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd Edition.Cephalalgia. 2018; 38: 1-211
- Chronic migraine: risk factors, mechanisms and treatment.Nat Rev Neurol. 2016; 12: 455-464
- Migraine progression: a systematic review.Headache. 2019; 59: 306-338
- Seeds for success: lifestyle Management in Migraine.Cleve Clin J Med. 2019; 86: 741-749
- Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine.Neurology. 2015; 84: 688-695
- Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) study: a randomized trial.JAMA. 2000; 284: 2599-2605
- Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of Migraine.Brain. 2019; 142: 1894-1904
- Lasmiditan is an effective acute treatment for migraine.Neurology. 2018; 91: e2222-e2232
- Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study.J Clin Pharmacol. 2019; 60: 495-504
- Evaluation of ly573144 (lasmiditan) in a preclinical model of medication overuse headache.Cephalalgia. 2020; 40: 903-912
- Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of Migraine.JAMA. 2019; 322: 1887
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of Migraine: a randomised, phase 3, double-blind, placebo-controlled trial.The Lancet. 2019; 394: 737-745
- Ubrogepant for the treatment of Migraine.N Engl J Med. 2019; 381: 2230-2241
- Within-person analysis of ubrogepant treatment of mild versus moderate-severe headache pain during a phase 3 long-term safety extension trial (S31.006).Neurology. 2022; 98: 167
- Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for Migraine. Headache.J Head Face Pain. 2020; 60: 1734-1742
- Anti-migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice.Ann Neurol. 2020; 88: 771-784
- TOP-PRO Study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.Cephalalgia. 2022; 42: 396-408
- Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.PLoS One. 2019; 14: e0212785
- Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial.Acta Neurol Scand. 2017; 135: 476-483
- Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study.Scientific Rep. 2021; 11: 3846
- Preventive migraine treatment.Continuum. 2015; 21: 973-989
- The american headache society consensus statement: update on integrating new migraine treatments into clinical practice.Headache. 2021; 61: 1021-1039
- Chronic migraine.BMJ. 2014; 348https://doi.org/10.1136/bmj.g1416
- Chronic migraine--classification, characteristics and Treatment.Nat Rev Neurol. 2012; 8: 162-171
- Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.Headache. 2007; 47: 170-180
- Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.Cephalalgia. 2007; 27: 814-823
- Preventive migraine treatment.Continuum. 2021; 27: 613-632
- Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials.Neurol Sci. 2010; 31: 23-28
- The effect of sodium valproate on chronic daily headache and its subgroups.J Headache Pain. 2008; 9: 37-41
- Gabapentin in the prophylaxis of chronic daily headache.Neurology. 2003; 61: 1753-1759
- Pregabalin in the treatment of chronic migraine: an open-label study.Clin Neuropharmacol. 2010; 33: 35-39
- Zonisamide is effective in the preventive therapy of chronic migraine: doc 551.J Headache Pain. 2013; 14: 1
- Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study.Headache. 2011; 51: 287-291
- Zonisamide for migraine prophylaxis in patients refractory to topiramate.Clin Neuropharmacol. 2009; 32: 103-106
- The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension.Headache. 2015; 55: 161-166
- Amitriptyline in the prophylactic treatment of migraine and chronic daily headache.Headache. 2011; 51: 33-51
- Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study.Headache. 2016; 56: 1626-1634
- An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache.J Clin Psychiatry. 2008; 69: 1449-1454
- Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study.Headache. 2013; 53: 1430-1437
- Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults.Curr Pain Headache Rep. 2019; 23: 85-88
- Other preventive anti-migraine treatments: ACE inhibitors, ARBS, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists.Curr Treat Options Neurol. 2019; 21: 17
- A comparative study of Candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study.Cephalalgia. 2013; 34: 523-532
- Candesartan in migraine prevention: results from a retrospective real-world study.J Neurol. 2020; 267: 3243-3247
- Atenolol in the Prophylaxis of Chronic Migraine: a 3-Month Open-Label Study.SpringerPlus. 2013; 2: 479
- Olanzapine in the treatment of refractory migraine and chronic daily headache.Headache. 2002; 42: 515-518
- Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.Headache. 2002; 42: 470-482
- Memantine for the prevention of primary headache disorders.Ann Pharmacother. 2014; 48: 1507-1511
- Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2B/3 trial.Lancet Neurol. 2020; 19: 727-737
- Abbvie. Press release. AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine.(Available at:) (Accessed March 10, 2022)
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults.Neurology. 2012; 78: 1337-1345
- Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache.Neurology. 2016; 86: 1818-1826
- Therapeutic novelties in Migraine: new drugs, new hope?.J Headache Pain. 2019; 20: 37
- The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.Cephalalgia. 2019; 40: 28-38
- Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.Cephalalgia. 2019; 39: 1455-1464
- History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from Translational Research to treatment.Headache. 2018; 58: 238-275
- Raynaud's phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists.Headache. 2019; 59: 1360-1364
- Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with raynaud phenomenon.JAMA Netw Open. 2021; 4: e217934
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine.J Headache Pain. 2018; 19: 92
- Headache in pregnancy and lactation.Continuum (Minneap Minn). 2022; 28: 72-92
- Safety and tolerability of preventive treatment options for chronic migraine.Expert Opin Drug Saf. 2021; 20: 1523-1533
- Efficacy and safety of eptinezumab in patients with chronic migraine.Neurology. 2020; 94: e1365-e1377
- Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects.J Neurol Neurosurg Psychiatr. 2021; 92: 1325-1334
- Eptinezumab for prevention of chronic migraine: a randomized phase 2B clinical trial.Cephalalgia. 2019; 39: 1075-1085
- Arise: a phase 3 randomized trial of erenumab for episodic migraine.Cephalalgia. 2018; 38: 1026-1037
- A controlled trial of erenumab for episodic migraine.N Engl J Med. 2017; 377: 2123-2132
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.Lancet Neurol. 2017; 16: 425-434
- Vascular safety of erenumab for migraine prevention.Neurology. 2019; 94: 1052
- Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study.Neurology. 2019; 92: e2250-e2260
- Effect of fremanezumab compared with placebo for prevention of episodic migraine.JAMA. 2018; 319: 1999
- Fremanezumab for the preventive treatment of chronic migraine.N Engl J Med. 2017; 377: 2113-2122
- Galcanezumab in chronic migraine.Neurology. 2018; 91: e2211-e2221
- Effect of different doses of galcanezumab vs placebo for episodic migraine prevention.JAMA Neurol. 2018; 75: 187
- Evaluation of galcanezumab for the prevention of episodic migraine.JAMA Neurol. 2018; 75: 1080
- A review in the prevention of chronic migraine.Drugs. 2018; 78: 589-600
- OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.Headache. 2010; 50: 921-936
- Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.J Neurol Neurosurg Psychiatr. 2015; 86: 996-1001
- Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains.Cephalalgia. 2014; 34: 853-869
- Pain associated with injection of botulinum a exotoxin reconstituted using isotonic sodium chloride with and without preservative.Arch Dermatol. 2002; 138: 510
- Flu-like symptoms following botulinum toxin therapy.Toxicon. 2011; 58: 1-7
- Chronic Migraine Treatment Trial Research Group. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine.Neurology. 2012; 78: 976-984
- Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study.Anesth Pain Res. 2020; 4: 1-4
- Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis.J Pain Palliat Care Pharmacother. 2021; 35: 1-6
- Efficacy and tolerability of calcitonin gene-related peptide targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine.Pain Med. 2021; 22: 1857-1863
- Real-World evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review.Pain Ther. 2021; 10: 809-826
- Combined Prophylactic treatment of chronic migraine with OnabotulinumtoxinA and Anti-CGRP monoclonal antibodies (P14-2.001).Neurology. 2022; 98: 14
- Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study.Neurology. 2016; 87: 529-538
- Update of neuromodulation in chronic migraine.Curr Pain Headache Rep. 2021; 25: 71
- Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2007; 6: 1054-1062
- Prognosis following discontinuation of OnabotulinumA Therapy in "Super-responding" Chronic Migraine Patients.Headache. 2019; 59: 1279-1285
- Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.Cephalalgia. 2022; 42: 326-334
Article info
Publication history
Published online: October 31, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
